Drug persistence is similar with rivastigmine and donepezil in Alzheimer's disease patients

被引：0
|
作者：
Mauskopf, J
Paramore, C
Lee, WC
McBurney, CR
Snyder, EH
机构：
[1] Res Triangle Inst, Chapel Hill, NC USA
[2] MEDTAP Int, Bethesda, MD USA
[3] Abt Associates Inc, Bethesda, MD USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
NEUROBIOLOGY OF AGING | 2004年 / 25卷
关键词：
D O I：
10.1016/S0197-4580(04)80685-7
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
下载
收藏
页码：S204 / S204
页数：1
相关论文
共 50 条
  • [1] Drug persistence patterns similar for rivastigmine-treated patients and donepezil-treated patients
    Mauskopf, J
    Paramore, C
    Lee, WC
    Snyder, EH
    VALUE IN HEALTH, 2003, 6 (06) : 771 - 771
  • [2] Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
    Bullock, R
    Bergman, H
    Touchon, J
    Gambina, G
    He, YS
    Nagel, J
    Lane, R
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (03) : 483 - 494
  • [3] Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma, JC
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (06) : 414 - 415
  • [4] Drug persistency of two cholinesterase inhibitors - Rivastigmine versus donepezil in elderly patients with Alzheimer's disease
    Suh, DC
    Thomas, SK
    Valiyeva, E
    Arcona, S
    Vo, L
    DRUGS & AGING, 2005, 22 (08) : 695 - 707
  • [5] Drug persistency of two cholinesterase inhibitors - Rivastigmine versus donepezil among elderly patients with Alzheimer's disease
    Suh, DC
    Thomas, SK
    Valiyeva, E
    Arcona, S
    Vo, L
    VALUE IN HEALTH, 2005, 8 (03) : 315 - 316
  • [6] Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
    Blesa, Rafael
    Bullock, Roger
    He, Yunsheng
    Bergman, Howard
    Gambina, Giuseppe
    Meyer, Joanne
    Rapatz, Guenter
    Nagel, Jennifer
    Lane, Roger
    PHARMACOGENETICS AND GENOMICS, 2006, 16 (11): : 771 - 774
  • [7] Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine
    Sicras-Mainar, A.
    Vergara, J.
    Leon-Colombo, T.
    Febrer, L.
    Rejas-Gutierrez, J.
    REVISTA DE NEUROLOGIA, 2006, 43 (08) : 449 - 453
  • [8] ANTIPSYCHOTIC DRUG USE IN PATIENTS WITH ALZHEIMER'S DISEASE TREATED WITH RIVASTIGMINE VERSUS DONEPEZIL: EVIDENCE FROM HEALTH CLAIMS DATA
    Lefebvre, P.
    Vekeman, F.
    Kahler, K.
    Mody-Patel, N.
    Duh, M. S.
    Scharre, D. W.
    VALUE IN HEALTH, 2009, 12 (03) : A196 - A197
  • [9] Psychotropic drug use in patients with Alzheimer's disease receiving rivastigmine
    Verny, M
    Fremont, P
    Bourrin, J
    Bourdeix, I
    Pere, J
    Toulouse, M
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S383 - S383
  • [10] Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease
    Kaasinen, V
    Någren, K
    Järvenpää, T
    Roivainen, A
    Yu, MX
    Oikonen, V
    Kurki, T
    Rinne, JO
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) : 615 - 620
12345